Baby exemestane vs. baby tamoxifen for high-risk breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial is testing two low-dose hormone therapies (exemestane and tamoxifen) to see which works better for preventing breast cancer in postmenopausal women who are at high risk. It's a double-blind study, so neither you nor your doctor will know which drug you're taking.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are postmenopausal (no period for 12 months or confirmed by a blood test).
- You have had certain breast conditions like DCIS, ADH, LCIS, or ALH within the past few years, or have a high risk score on a breast cancer risk calculator, or carry a CHEK2 or ATM gene variant, or received chest radiation before age 30.
- You are able to swallow pills and are in generally good health (ECOG 0-1).
- You have had a mammogram within the last 6 months and a bone density scan (DEXA) within the last year.
- You have not used hormone replacement therapy in the last 3 months or antiestrogen drugs in the last year.
- You do not have a history of blood clots, endometrial cancer, severe osteoporosis, or certain eye problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two low-dose medications, exemestane and tamoxifen, to see which is better at preventing breast cancer in postmenopausal women who have a higher risk. You would take one of these pills daily for a few years, and the study will check how well it works and what side effects occur.
This trial tests a new hormone therapy pill (elacestrant) against standard hormone therapy for people with a common type of early breast cancer (ER+, HER2-) that has a higher chance of returning. You may qualify if you've already been on hormone therapy for 2 to 5 years and want to see if a different pill works better.
This trial tests a new oral drug (HRS-8080) against standard hormone therapy for women with intermediate- or high-risk early breast cancer who have already completed 2 to 5 years of hormone treatment. It aims to see if the new drug can reduce the risk of cancer coming back.
This trial tests a new hormone therapy drug called elacestrant against standard hormone treatments for people with a specific type of early breast cancer (ER+/HER2-) that has a high chance of coming back. The goal is to see if elacestrant works better at keeping the cancer from returning.
This trial tests if taking hormone therapy for 5 more years helps prevent breast cancer from coming back. It is for women who have already completed 5 years of tamoxifen or an aromatase inhibitor and had lymph node involvement at diagnosis.
This trial tests combining elacestrant (a new hormone therapy) with exemestane (a standard hormone therapy) for people whose HR+/HER2- breast cancer has spread and who have already tried a CDK4/6 inhibitor with anastrozole or letrozole. It may help if your tumor shows certain activity on a special PET scan.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.